Virtual ASCO 2020 Highlights
June 23, 2020
Share:
The coronavirus pandemic forced ASCO to shift their 2020 Annual Meeting into an online format for the first time, but the conference remained a key forum for cancer innovation—an area to which Clarion is committed. We are pleased to share our perspectives on some of the most impactful new data at the virtual event:
Key Takeaways
- IO expands vertically: Checkpoint inhibitors rack up more successes in the frontline setting
- IO expands horizontally: Data support new immune MoAs, combinations, and indications
- Targeted therapy: EGFR and HER2 therapies expand their reach, and novel mechanisms emerge
- Hematology-oncology: Excitement continues for BCMA in myeloma, CD47 in AML/MDS, and other novel approaches
- COVID-19: Real-world data confirms the new threat to cancer patients